Market revenue in 2023 | USD 8.1 million |
Market revenue in 2030 | USD 24.5 million |
Growth rate | 17.2% (CAGR from 2023 to 2030) |
Largest segment | Pneumococcal conjugate vaccine |
Fastest growing segment | Pneumococcal Conjugate Vaccine |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine |
Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Walvax Biotechnology, Beijing Minhai Biotechnology Co. |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pneumococcal vaccine market will help companies and investors design strategic landscapes.
Pneumococcal conjugate vaccine was the largest segment with a revenue share of 92.59% in 2023. Horizon Databook has segmented the Thailand pneumococcal vaccine market based on pneumococcal conjugate vaccine, pneumococcal polysaccharide vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
In October 2023, Walvax Biotechnology Co., Ltd. launched Weuphoria, a 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), in Bangkok, Thailand. This event saw the participation of esteemed experts, senior pediatricians, parents, and children, highlighting the significance of the vaccine in combating pneumococcal diseases.
Thailand's approval of Weuphoria marks the second overseas market after Morocco to approve Walvax's PCV13. This achievement enhances the vaccine's recognition in the international market and facilitates its access to more countries worldwide.
The introduction of Weuphoria by Walvax Biotechnology presents a significant development in the pneumococcal vaccine market in Thailand. With its tailored serotype coverage and endorsement from key opinion leaders, Weuphoria is poised to address the healthcare needs of Thai children, contributing to the overall growth of the pneumococcal vaccine market in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand pneumococcal vaccine market, including forecasts for subscribers. This country databook contains high-level insights into Thailand pneumococcal vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account